BRIEF-肯定的な Results From AstraZeneca Flaura2 段階 III 裁判，公判
Sept 11 (Reuters) - AstraZeneca PLC:
* TAGRISSO PLUS CHEMOTHERAPY EXTENDED MEDIAN PROGRESSION-FREE SURVIVAL IN FLAURA2 PHASE III TRIAL
* RESULTS SHOWED TAGRISSO PLUS CHEMOTHERAPY REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 38% COMPARED TO TAGRISSO ALONE
* COMBINATION REDUCED RISK OF DISEASE PROGRESSION BY 38% VERSUS TAGRISSO MONOTHERAPY, CURRENT 1ST-LINE GLOBAL STANDARD OF CARE
* AT TIME OF ANALYSIS, OVERALL SURVIVAL DATA WERE IMMATURE HOWEVER, A FAVOURABLE TREND WAS OBSERVED FOR TAGRISSO PLUS CHEMOTHERAPY Source text for Eikon: その上の company ニュース報道: (Gdansk Newsroom)
